Stan Wong
Member since: Jun '09
Director & Portfolio Manager at
Private Wealth Management, ScotiaMcleod
Private Wealth Management, ScotiaMcleod
2221 Opinions
Latest Top Picks
(A Top Pick Jan 30/20, Up 18%) Continues to buy. Growth from emerging markets over the next 10 years is quite strong. Normalization of activity will bring revenue to pre-pandemic levels by 2022. Diversified.
(A Top Pick Jan 30/20, Down 1%) Still likes. Continues to buy. Discount to other big pharma. Cancer drugs are very high margin. Pandemic has spurred pharma sales. Will benefit as life returns to normal. Yield is 3.1%.
(A Top Pick Jan 30/20, Up 20%) Revenue has responded well to pandemic. Digital initiatives acting very well. Pay a premium at 36x forward earnings for 15% growth. Strong, iconic name. Cautious on buying going forward, based on valuation.
Down about 30%. Buying opportunity. Long-term secular e-commerce growth. Middle class growth provides a runway of increased earnings. Trading at 20x earnings for 20% growth. No dividend. (Analysts’ price target is $331.03)
Premier shopping mall in the US. Unique shopping experiences. Post-Covid, the outlook is impressive. Yield is 5.99%. (Analysts’ price target is $96.47)
Signal
Opinion
Expert
Chart
COMMENT
COMMENT
January 13, 2021
Will there be a recovery in the economy? It's going to be a bumpy ride. Covid is in control socially and economically right now. Markets always look forward 6-9 months, so he's optimistic of a path towards good returns for equities, despite bouts of volatility.
Show full opinionHide full opinion
Will there be a recovery in the economy? It's going to be a bumpy ride. Covid is in control socially and economically right now. Markets always look forward 6-9 months, so he's optimistic of a path towards good returns for equities, despite bouts of volatility.
COMMENT
COMMENT
January 13, 2021
Interested in retail or travel? Some of the cyclicals, including retailers, consumer discretionary, travel, leisure. They've moved higher since the vaccine announcements. Going forward 12 months out, they'll be positive.
Show full opinionHide full opinionInterested in retail or travel? Some of the cyclicals, including retailers, consumer discretionary, travel, leisure. They've moved higher since the vaccine announcements. Going forward 12 months out, they'll be positive.
COMMENT
COMMENT
January 13, 2021
Are dividend stocks vulnerable with the bond yields moving up? He likes dividend growers over dividend payers. As interest rates move up at the long end of the curve, that can affect some of the flat dividend payers.
Show full opinionHide full opinionAre dividend stocks vulnerable with the bond yields moving up? He likes dividend growers over dividend payers. As interest rates move up at the long end of the curve, that can affect some of the flat dividend payers.
HOLD
HOLD
January 13, 2021
Likes it. Tracks a basket of high-dividend paying stocks on the TSX. Banks, pipelines, telecom. About 40% is in cyclicals. Yield is about 5%.
Show full opinionHide full opinionLikes it. Tracks a basket of high-dividend paying stocks on the TSX. Banks, pipelines, telecom. About 40% is in cyclicals. Yield is about 5%.
DON'T BUY
DON'T BUY
January 13, 2021
Parabolic in last little while. Now overbought. 200x forward earnings, 35% growth, 5-6x PEG, 18x price to sales. Not cheap. Risk of competition from the big players. Based on technicals and fundamentals, be cautious.
Show full opinionHide full opinionParabolic in last little while. Now overbought. 200x forward earnings, 35% growth, 5-6x PEG, 18x price to sales. Not cheap. Risk of competition from the big players. Based on technicals and fundamentals, be cautious.
BUY
BUY
January 13, 2021
Has done well because of stay at home. The way of the future. Virtual visits make a lot of sense. Revenue should continue to grow. Higher beta. Long-term secular growth play.
Show full opinionHide full opinionHas done well because of stay at home. The way of the future. Virtual visits make a lot of sense. Revenue should continue to grow. Higher beta. Long-term secular growth play.
Healthcare
DON'T BUY
DON'T BUY
January 13, 2021
Lagged higher growth areas since at least 2017. Yield is great at 5.1%. A tech company with high yield signals to him that growth is starting to stall. Be cautious. Cheap for a reason. Revenue growth looks anemic. Fine for income, not for growth.
Show full opinionHide full opinionLagged higher growth areas since at least 2017. Yield is great at 5.1%. A tech company with high yield signals to him that growth is starting to stall. Be cautious. Cheap for a reason. Revenue growth looks anemic. Fine for income, not for growth.
electrical/electronic
PARTIAL SELL
PARTIAL SELL
January 13, 2021
Good name in the TSX. One of the better growth names. 15% growth rate going forward. 24x forward PE. He's not into consumer staples at this point, favours cyclicals.
Show full opinionHide full opinionGood name in the TSX. One of the better growth names. 15% growth rate going forward. 24x forward PE. He's not into consumer staples at this point, favours cyclicals.
Consumer Products
BUY
BUY
January 13, 2021
MFC vs. GWO Likes Great West in his portfolio because of its strong yield of about 4.76%. MFC dividend is 4.63%. Both have performed well since March 2020. Quite similar. MFC provides more foreign exposure, especially Asia. Insurers are doing well now, and benefit from steepening yield curves.
MFC vs. GWO Likes Great West in his portfolio because of its strong yield of about 4.76%. MFC dividend is 4.63%. Both have performed well since March 2020. Quite similar. MFC provides more foreign exposure, especially Asia. Insurers are doing well now, and benefit from steepening yield curves.
insurance
BUY
BUY
January 13, 2021
GWO vs. MFC Likes Great West because of its strong yield of about 4.76%. CMF dividend is 4.63%. Both have performed well since March 2020. Quite similar. MFC provides more foreign exposure, especially Asia. Insurers are doing well now, and benefit from steepening yield curves.
GWO vs. MFC Likes Great West because of its strong yield of about 4.76%. CMF dividend is 4.63%. Both have performed well since March 2020. Quite similar. MFC provides more foreign exposure, especially Asia. Insurers are doing well now, and benefit from steepening yield curves.
insurance
HOLD
HOLD
January 13, 2021
He holds Costco instead, as it brings in 3x as much in sales. WMT is a good name, but has lower growth prospects. Trying to enhance their digital experience, and he can't predict results just yet. 26x earnings, 6% earnings growth. Not cheap, but not expensive.
department stores
BUY
BUY
January 13, 2021
Creating a huge base since last year. Has moved since vaccine announcements. Bumpy ride ahead. Two years forward, it will continue to recover as business activity normalizes. For the higher octane part of your portfolio. Be patient, and it should do well.
Show full opinionHide full opinionCreating a huge base since last year. Has moved since vaccine announcements. Bumpy ride ahead. Two years forward, it will continue to recover as business activity normalizes. For the higher octane part of your portfolio. Be patient, and it should do well.
Transportation
PAST TOP PICK
PAST TOP PICK
January 13, 2021
(A Top Pick Jan 30/20, Up 18%) Continues to buy. Growth from emerging markets over the next 10 years is quite strong. Normalization of activity will bring revenue to pre-pandemic levels by 2022. Diversified.
Show full opinionHide full opinion(A Top Pick Jan 30/20, Up 18%) Continues to buy. Growth from emerging markets over the next 10 years is quite strong. Normalization of activity will bring revenue to pre-pandemic levels by 2022. Diversified.
department stores
PAST TOP PICK
PAST TOP PICK
January 13, 2021
(A Top Pick Jan 30/20, Down 1%) Still likes. Continues to buy. Discount to other big pharma. Cancer drugs are very high margin. Pandemic has spurred pharma sales. Will benefit as life returns to normal. Yield is 3.1%.
Show full opinionHide full opinion(A Top Pick Jan 30/20, Down 1%) Still likes. Continues to buy. Discount to other big pharma. Cancer drugs are very high margin. Pandemic has spurred pharma sales. Will benefit as life returns to normal. Yield is 3.1%.
biotechnology/pharmaceutical
PAST TOP PICK
PAST TOP PICK
January 13, 2021
(A Top Pick Jan 30/20, Up 20%) Revenue has responded well to pandemic. Digital initiatives acting very well. Pay a premium at 36x forward earnings for 15% growth. Strong, iconic name. Cautious on buying going forward, based on valuation.
Show full opinionHide full opinion(A Top Pick Jan 30/20, Up 20%) Revenue has responded well to pandemic. Digital initiatives acting very well. Pay a premium at 36x forward earnings for 15% growth. Strong, iconic name. Cautious on buying going forward, based on valuation.
food services
PixFuture exclusive partner.
© Stockchase Inc.